The first-in-class erythroid maturation agent luspatercept (Reblozyl) is already approved for the treatment of anemia in adult patients with beta thalassemia who require red blood cell (RBC) transfusions. Now it has also shown to be beneficial for patients with beta thalassemia who are not dependent on transfusions. There is no drug specifically indicated as yet